The European Medicines Agency has recommended for EU-wide approval nine new drugs, including three orphan medicines – BeiGene’s Brukinsa (zanubrutinib) for treating Waldenström’s macroglobulinemia, Deciphera Pharmaceuticals’ Qinlock (ripretinib) for advanced gastrointestinal stromal tumor, and Amivas’ malaria drug, Artesunate Amivas.
Gavreto (pralsetinib), Roche/Blueprint Medicines’ treatment for non-small cell lung cancer (NSCLC), and Vumerity (diroximel fumarate), Biogen/Alkermes treatment...








